ACHV News and Press, Achieve Life Sciences Inc. From 10/08/20

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / October 8, 2020 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it...

Achieve Life Sciences (ACHV) has initiated Phase 3 ORCA-2 clinical trial, evaluating the efficacy and safety of 3 mg cytisinicline dosed 3 times daily compared to placebo in 750 adult smokers at 15 clinical sites in the U.S.The participants will be randomized to one of three study arms of cyt...

Achieve Life Sciences Announces Start of Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline for Smoking Cessation Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo Phase 3 ORCA-2 Trial to Enroll 750 Smokers Acro...

Achieve Life Sciences (ACHV) promotes John Bencich to Chief Executive Officer. Mr. Bencich has been serving as Achieve's Chief Financial and Operating Officer since 2017.Rick Stewart, company's current Chairman and CEO, will continue as Executive Chairman.Additionally, Dr. ...

Achieve Life Sciences Announces Appointment of John Bencich to Chief Executive Officer & Dr. Cindy Jacobs to President Achieve Life Sciences Announces Appointment of John Bencich to Chief Executive Officer & Dr. Cindy Jacobs to President Canada NewsWire SEATTLE a...

Achieve Life Sciences ( ACHV +18.0% )  announced presentation of final results from the RAUORA trial evaluating the effectiveness and safety of cytisinicline compared to Pfizer's varenicline as a smoking cessation aid in 679 participants. Results were presented at the Society for Res...

SEATTLE and VANCOUVER, BC , Sept. 18, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced pr...

A study was conducted at the University of Cambridge Department of Biochemistry, was designed to examine the in vitro binding characteristics of Achieve Life Sciences' (NASDAQ: ACHV )  cytisinicline compared to varenicline at the human 5-HT 3  receptor (directly leads to naus...

SEATTLE , and VANCOUVER, British Columbia , Sept. 18, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced data prese...

The following slide deck was published by Achieve Life Sciences, Inc. in conjunction with this Read more ...